J&J Sees International OTC Presence, Pfizer Pickups As Growth Engines
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm expects to launch OTC Zyrtec without exclusivity at year-end, and looks to the antihistamine product as well as Nicorette and new products using rapid release technology expected as growth drivers.